

Screen failures N=84
Not randomized due to study completion N=1
Screened* N=154
Placebo (Randomized and treated) N=35
Early discontinued the study (N=2)
Completed study (N=1)
Dose reduced (N=1)
Completed Study N=(1)
Compound (1) 60mg (Randomized and treated) N=34
Early discontinued the study at 60mg (N=5)
Completed the study at 60mg dose (N=8)
Dose reduced to 45mg (N=19)
Early discontinued the study at 45mg (N=3)
Completed the study at 45mg (N=5)
Dose further reduced to 30mg (N=11)
Dose reduced directly to 30mg (N=2)
Early discontinued the study at 30mg (N=1)
Completed the study at 30mg (N=1)
Early discontinued the study at 30mg (N=4)
Completed the study at 30mg (N=7)

FIG. 1



LS MEAN CHANGE FROM BASELINE IN TETRAS PERFORMANCE SUBSCALE
PART 4 UPPER LIMB TREMOR TOTAL SCORE OVER TIME BY TREATMENT GROUP
(FULL ANALYSIS SET)
LS Mean Change (SE)
0
-1
-2
-3
Baseline
Day 8
Day 15 Predose
Day 15, 5 hours post dose
Day 15, 8 hours post dose
Day 22
Day 29
Day 42
0.0468
0.3124
0.5148
0.6452
0.1171
0.0491
0.2724
Timepoint (Days)
Placebo N=34
Compound (1) N=33

FIG. 2



FOREST PLOT OF CHANGE FROM BASELINE IN TETRAS PERFORMANCE
SUBSCALE PART 4 UPPER LIMB TREMOR TOTAL SCORE AT DAY 29 (FULL ANALYSIS SET)
Compound
Subgroups Placebo (1) LS Mean Diff LCL UCL Pvalue
Overall 33 21 -1.07 -2.1 0 0.0491
Age Group
<65 years 10 7 -1.36 -4 1.3 0.2835
65-80 years 23 14 -1.21 -2.4 0 0.0483
Sex
Male 13 14 -1.47 -3.1 0.1 0.0721
Female 20 7 -0.21 -1.8 1.4 0.7838
Race
White 30 19 -1.42 -2.5 -0.3 0.0104
Black or African American or Other 3 2 2.9 -0.4 6.2 0.0846
BMI
<18.5 kg/m2 or 18.5-<25 kg/m2 12 2 -0.71 -4.2 2.8 0.6680
25-<30 kg/m2 11 10 -1.48 -3.4 0.4 0.1241
>=30 kg/m2 10 9 -0.82 -2.2 0.6 0.2424
Age at ET diagnoses
<40 years 9 3 -1.14 -3.9 1.6 0.3725
40-60 years 15 9 -1.64 -3.2 0 0.0454
>60 years 9 9 -1.03 -3.2 1.1 0.3291
Age subject thinks ET started
<40 years 21 9 -0.48 -1.9 1 0.5066
40-60 years 8 10 -1.89 -3.7 -0.1 0.0404
>60 years 4 2 0.11 -4.3 4.5 0.9608
Years with ET diagnosis
3-<6 years 3 5 -0.55 -3.2 2.1 0.6765
6-10 years 6 8 -0.38 -2.7 2 0.7347
>10 years 24 8 -1.24 -2.7 0.2 0.0833
Years since subject thinks ET started
3-<6 years or 6-10 years 2 3 0.64 -4.9 6.2 0.8107
>10 years 31 18 -1.27 -2.4 -0.2 0.0233
Alcohol helps tremor
Yes 6 1 -4.21 -5.8 -2.6 <0001
No 14 11 -2.03 -3.6 -0.4 0.0139
NA 13 9 0.42 -1.3 -2.1 0.6129
Baseline TETRAS Upper Limb Score
<12 12 4 0.45 -2.2 3.1 0.7209
>=12 21 17 -1.7 -2.9 -0.5 0.0066
LS Mean Diff and 95% CI
-5 -2.5 0 2.5 5
Favors Treatment
Favors Placebo
Treatment: ___Compound (1)

FIG. 3



LS MEAN CHANGE FROM BASELINE IN TETRAS PERFORMANCE SUBSCALE
PART 4 UPPER LIMB TREMOR TOTAL SCORE OVER TIME BY TREATMENT GROUP
(BASELINE TETRAS PERFORMANCE PART 4 UPPER LIMB SCORE ≥ 12)
LS Mean Change (SE)
0
-1
-2
-3
-4
Baseline
Day 8
Day 15 Predose
Day 15, 5 hours post dose
Day 15, 8 hours post dose
Day 22
Day 29
Day 42
0.0096
0.0121
0.0147
0.0323
0.0088
0.0066
0.7486
Timepoint (Days)
Placebo N=22
Compound (1) N=25

FIG. 4



LS MEAN CHANGE FROM BASELINE IN TETRAS PERFORMANCE SUBSCALE
PART 4 UPPER LIMB TREMOR TOTAL SCORE OVER TIME BY TREATMENT GROUP
(PER-PROTOCOL SET)
LS Mean Change (SE)
0
-1
-2
-3
-4
Baseline
Day 8
Day 15 Predose
Day 15, 5 hours post dose
Day 15, 8 hours post dose
Day 22
Day 29
Day 42
0.0270
0.0876
0.2771
0.2793
0.0332
0.0214
0.5654
Timepoint (Days)
Placebo N=32
Compound (1) N=26

FIG. 5



LS MEAN CHANGE FROM BASELINE IN TETRAS ADL TOTAL SCORE OVER TIME BY TREATMENT GROUP
(FULL ANALYSIS SET)
LS Mean Change (SE)
0
-2
-4
-6
Baseline
Day 8
Day 15
Day 22
Day 29
Day 42
0.0193
0.0243
0.0385
0.2682
0.3649
Timepoint (Days)
Placebo N=34
Compound (1) N=33

FIG. 6



Forest Plot of Change from Baseline in TETRAS ADL Total Score at Day 29
Full Analysis Set
LS Mean Diff and 95% CI
Subgroups
Placebo
Compound (1)
LS Mean Diff
LCL
UCL
Pvalue
Overall 33 21 -1.37 -3.8 1.1 0.2682
Age Group
<65 years 10 7 0.34 -4.6 5.2 0.8864
65-80 years 23 14 -2.31 -5.1 0.5 0.1061
Sex
Male 13 14 -0.84 -4.6 2.9 0.6506
Female 20 7 -0.89 -4.9 3.2 0.6554
Race
White 30 19 -1.69 -4.2 0.8 0.1794
Black or African American or Other 3 2 4.44 -3.1 12 0.2194
BMI
<18.5 kg/m2 or 18.5-<25 kg/m2 12 2 3.32 -2.5 9.1 0.2385
25-<30 kg/m2 11 10 -3.52 -7.8 0.8 0.1043
>=30 kg/m2 10 9 -0.68 -4.9 3.5 0.7386
Age at ET diagnoses
<40 years 9 3 2.95 -1.2 7.1 0.1447
40-60 years 15 9 -0.71 -4.6 3.2 0.7067
>60 years 9 9 -6.29 -11.1 -1.5 0.0133
Age subject thinks ET started
<40 years 21 9 1.24 -2.2 4.7 0.4645
40-60 years 8 10 -3.78 -7.7 0.2 0.0603
>60 years 4 2 -9.49 -15.7 -3.3 0.0051
Years with ET diagnosis
3-<6 years 3 5 0.86 -8.4 11.1 0.8528
6-10 years 6 8 -2.52 -7.4 2.4 0.2891
>10 years 24 8 0.87 -2.3 4 0.5800
Years since subject thinks ET started
3-<6 years or 6-10 years 2 3 -12.32 -17.4 -7.2 0.0002
>10 years 31 18 -0.19 -2.7 2.3 0.8796
Alcohol helps tremor
Yes 6 1 -4.02 -10.6 2.5 0.2161
No 14 11 -1.53 -5 2 0.3739
NA 13 9 -1.08 -5.5 3.3 0.6126
Baseline ADL Score
<28 18 10 -1.17 -4.9 2.5 0.5244
>=28 15 11 -1.47 -5.4 2.5 0.4476
-20
-10
0
10
Favors Treatment
Favors Placebo
Treatment: ___ Compound (1)

FIG. 7



LS MEAN CHANGE FROM BASELINE IN TETRAS PERFORMANCE
TOTAL SCORE OVER TIME BY TREATMENT GROUP
(FULL ANALYSIS SET)
LS Mean Change (SE)
0
-2
-4
-6
-8
Baseline
Day 8
Day 15 Predose
Day 15, 5 hours post dose
Day 15, 8 hours post dose
Day 22
Day 29
Day 42
0.2478
0.4486
0.2662
0.9965
0.8437
0.7960
0.0456
Timepoint (Days)
Placebo N=34
Compound (1) N=33

FIG. 8



Forest Plot of Change from Baseline in TETRAS Total Performance Score Day 29
Full Analysis Set
LS Mean Diff and 95% CI
Subgroups
Placebo
Compound (1)
LS Mean Diff
LCL
UCL
Pvalue
Overall 33 21 -0.32 -2.8 2.1 0.7960
Age Group
<65 years 10 7 0.15 -4.7 5 0.9484
65-80 years 23 14 -0.59 -3.6 2.4 0.6958
Sex
Male 13 14 -1.58 -5.2 2 0.3766
Female 20 7 2.32 -1.4 6 0.2122
Race
White 30 19 -1.4 -3.8 1 0.2457
Black or African American or Other 3 2 1.1 5.2 16.8 0.0009
BMI
<18.5 kg/m2 or 18.5-<25 kg/m2 12 2 -3.13 -12.2 6 0.4660
25-<30 kg/m2 11 10 -1.18 -5.9 3.5 0.6064
>=30 kg/m2 10 9 0.64 -2.5 3.7 0.6719
Age at ET diagnoses
<40 years 9 3 0.73 -5.5 7 0.7996
40-60 years 15 9 -1.35 -5.3 2.6 0.4881
>60 years 9 9 -0.26 -4.8 4.3 0.9065
Age subject thinks ET started
<40 years 21 9 0.09 -3.4 3.6 0.9606
40-60 years 8 10 -2.48 -6.7 1.8 0.2413
>60 years 4 2 3.31 -5.7 12.3 0.4546
Years with ET diagnosis
3-<6 years 3 5 2.72 -3.1 8.6 0.3532
6-10 years 6 8 1.24 -4.4 6.9 0.6429
>10 years 24 8 -0.46 -3.9 3 0.7888
Years since subject thinks ET started
3-<6 years or 6-10 years 2 3 3.81 -7.3 14.9 0.4822
>10 years 31 18 -0.71 -3.3 1.9 0.5847
Alcohol helps tremor
Yes 6 1 -2.15 -8.2 3.9 0.4764
No 14 11 -2.64 -5.7 0.4 0.0910
NA 13 9 2.14 -2.4 6.7 0.3411
Baseline TETRAS Upper Limb Score
<12 12 4 3.84 -2 9.7 0.1860
>=12 21 17 -1.9 -4.7 0.8 0.1702
-10
0
10
Favors Treatment
Favors Placebo
Treatment: ___Compound (1)

FIG. 9




LS MEAN CHANGE FROM BASELINE IN TETRAS PERFORMANCE SUBSCALE PART
4/6/7/8 TOTAL SCORE OVER TIME BY TREATMENT GROUP
(FULL ANALYSIS SET)
LS Mean Change (SE)
0
-1
-2
-3
-4
-5
-6
Baseline
Day 8
Day 15 Predose
Day 15, 5 hours post dose
Day 15, 8 hours post dose
Day 22
Day 29
Day 42
0.1337
0.5511
0.3608
0.8237
0.4105
0.5331
0.0368
Timepoint (Days)
Placebo N=34
Compound (1) N=33

FIG. 10



Subgroups	Placebo	Compound (1)	LS Mean Diff	LCL	UCL	Pvalue
Overall	33	21	-0.59	-2.5	1.3	0.5331
Age Group						
<65 years	10	7	-0.29	-4.6	4	0.8886
65-80 years	23	14	-0.63	-2.9	1.6	0.5716
Sex						
Male	13	14	-1.41	-4.1	1.3	0.2957
Female	20	7	1.26	-1.6	4.1	0.3731
Race						
White	30	19	-1.44	-3.3	0.4	0.1165
Black or African American or Other	3	2	8.74	-3.8	13.6	0.0016
BMI						
<18.5 kg/m2 or 18.5-<25 kg/m2	12	2	-0.88	-7.3	5.5	0.7731
25-<30 kg/m2	11	10	-1.01	-4.6	2.5	0.5629
>=30 kg/m2	10	9	-0.81	-3.1	1.5	0.4732
Age at ET diagnoses						
<40 years	9	3	0.88	-2.2	4	0.5686
40-60 years	15	9	-2.24	-5.2	0.7	0.1350
>60 years	9	9	0.34	-2.9	3.6	0.8286
Age subject thinks ET started						
<40 years	21	9	0.03	-2.6	2.7	0.9812
40-60 years	8	10	-2.67	-6.1	0.7	0.1189
>60 years	4	2	3.61	-2.9	10.1	0.2611
Years with ET diagnosis						
3-<6 years	3	5	1.49	-2	4.9	0.3861
6-10 years	6	8	1.03	-3.3	5.3	0.6137
>10 years	24	8	-1.2	-3.9	1.5	0.3714
Years since subject thinks ET started						
3-<6 years or 6-10 years	2	3	4.33	-3.6	12.3	0.2690
>10 years	31	18	-1.12	-3.1	0.8	0.2524
Alcohol helps tremor						
Yes	6	1	-2.75	-7.1	1.6	0.2111
No	14	11	-2.01	-4.5	0.5	0.1150
NA	13	9	1.31	-1.8	4.5	0.3987
Baseline TETRAS Upper Limb Score						
<12	12	4	3.09	-1	7.2	0.1306
>=12	21	17	-1.97	-4.1	0.1	0.0642

FIG. 11